Fortitude Family Office’s ClearPoint Neuro CLPT Stock Holding History

Fortitude Family Office’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$821	Hold	46	–	–	﹤0.01%	1823
2026 Q1	$419	Buy	+46	New	+$581	﹤0.01%	1788

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Fortitude Family Office's CLPT Position: Q2 2026 in Review

Fortitude Family Office held its ClearPoint Neuro (CLPT) position steady in Q2 2026 at 46 shares worth $821. The position accounts for ﹤0.01% of the portfolio, ranked #1823.

Fortitude Family Office first reported a position in CLPT in Q1 2026 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Fortitude Family Office held 46 shares of ClearPoint Neuro worth $821 as of Q2 2026.
Fortitude Family Office left its ClearPoint Neuro share count unchanged in Q2 2026.
ClearPoint Neuro made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1823 holding.
Fortitude Family Office first reported a position in ClearPoint Neuro in Q1 2026 and has held it in 2 quarters since.
129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.